CL2013001779A1 - Comprimido farmaceutico que comprende el solvato de dimetilsulfoxido de n-{3-[3-ciclopropil-5-(2-fluoro-4-yodo-fenilamino)-6,8-dimetil-2,4,7-trioxo-3,4,6,7-tetrahidro-2h-pirido[4,3-d]pirimidin-1-il]fenil}acetamida; procedimiento de preparacion; y su uso para tratar el cancer. - Google Patents
Comprimido farmaceutico que comprende el solvato de dimetilsulfoxido de n-{3-[3-ciclopropil-5-(2-fluoro-4-yodo-fenilamino)-6,8-dimetil-2,4,7-trioxo-3,4,6,7-tetrahidro-2h-pirido[4,3-d]pirimidin-1-il]fenil}acetamida; procedimiento de preparacion; y su uso para tratar el cancer.Info
- Publication number
- CL2013001779A1 CL2013001779A1 CL2013001779A CL2013001779A CL2013001779A1 CL 2013001779 A1 CL2013001779 A1 CL 2013001779A1 CL 2013001779 A CL2013001779 A CL 2013001779A CL 2013001779 A CL2013001779 A CL 2013001779A CL 2013001779 A1 CL2013001779 A1 CL 2013001779A1
- Authority
- CL
- Chile
- Prior art keywords
- trioxo
- pyrido
- phenylamino
- pyrimidin
- iodo
- Prior art date
Links
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 title 2
- -1 2-fluoro-4-iodo-phenylamino Chemical group 0.000 title 1
- 206010028980 Neoplasm Diseases 0.000 title 1
- METKIMKYRPQLGS-UHFFFAOYSA-N atenolol Chemical compound CC(C)NCC(O)COC1=CC=C(CC(N)=O)C=C1 METKIMKYRPQLGS-UHFFFAOYSA-N 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
- 239000012453 solvate Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61J3/00—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
- A61J3/06—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms into the form of pills, lozenges or dragees
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61J3/00—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
- A61J3/10—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms into the form of compressed tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2813—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201061424967P | 2010-12-20 | 2010-12-20 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2013001779A1 true CL2013001779A1 (es) | 2014-06-27 |
Family
ID=46314827
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2013001779A CL2013001779A1 (es) | 2010-12-20 | 2013-06-18 | Comprimido farmaceutico que comprende el solvato de dimetilsulfoxido de n-{3-[3-ciclopropil-5-(2-fluoro-4-yodo-fenilamino)-6,8-dimetil-2,4,7-trioxo-3,4,6,7-tetrahidro-2h-pirido[4,3-d]pirimidin-1-il]fenil}acetamida; procedimiento de preparacion; y su uso para tratar el cancer. |
Country Status (38)
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI505828B (zh) | 2010-12-20 | 2015-11-01 | 葛蘭素史克智慧財產（第二）有限公司 | 新穎醫藥組成物 |
| HK1206605A1 (en) | 2012-08-17 | 2016-01-15 | 霍夫曼-拉罗奇有限公司 | Combination therapies for melanoma comprising administering cobimetinib and vemurafinib |
| SG11201503688SA (en) * | 2012-11-30 | 2015-06-29 | Glaxosmithkline Llc | Novel pharmaceutical composition |
| WO2015019125A1 (en) * | 2013-08-05 | 2015-02-12 | Societe De Developpement Et De Recherche Industrielle | Molecular targets for the treatment of wounds, in particular chronic wounds |
| CN103819471A (zh) * | 2013-11-25 | 2014-05-28 | 镇江圣安医药有限公司 | 吡啶并(4,3-d)嘧啶-1（2H）-基苯基乙酰胺的衍生物及其应用 |
| WO2015081566A1 (zh) * | 2013-12-06 | 2015-06-11 | 杭州普晒医药科技有限公司 | 曲美替尼及其溶剂化物的晶型、其制备方法、含有它们的药物组合物及其用途 |
| EP2913048A1 (en) * | 2014-02-27 | 2015-09-02 | ratiopharm GmbH | Pharmaceutical composition comprising trametinib |
| WO2016126012A1 (en) * | 2015-02-05 | 2016-08-11 | Boryung Pharmaceutical Co., Ltd | Tablet and method of preparing the same |
| KR101545268B1 (ko) | 2015-02-05 | 2015-08-20 | 보령제약 주식회사 | 정제 및 이의 제조방법 |
| US20170020880A1 (en) * | 2015-07-22 | 2017-01-26 | Hetero Research Foundation | Pharmaceutical compositions of trametinib |
| CN116172869A (zh) * | 2016-08-10 | 2023-05-30 | 豪夫迈·罗氏有限公司 | 包含Akt蛋白激酶抑制剂的药物组合物 |
| RU2627692C1 (ru) | 2016-10-10 | 2017-08-10 | Закрытое акционерное общество "Р-Фарм" (ЗАО "Р-Фарм") | N-{ 3-[3-циклопропил-5-(2-фторо-4-иодофениламино)-6,8-диметил-2,4,7-триоксо-3,4,6,7-тетрагидро-2Н-пиридо[4,3-d]пиримидин-1-ил]-фенил} -циклопропанкарбоксамида диметилсульфоксида сольват в качестве ингибитора МЕК1/2 |
| TW201818936A (zh) * | 2016-11-25 | 2018-06-01 | 大陸商江蘇恆瑞醫藥股份有限公司 | 一種吡啶酮類衍生物醫藥組成物及其製備方法 |
| CN110494166B (zh) | 2017-05-02 | 2022-11-08 | 诺华股份有限公司 | 组合疗法 |
| BR112021022335A2 (pt) | 2019-05-13 | 2021-12-28 | Novartis Ag | Formas cristalinas de n-(3-(2-(2-hidroxietoxi)-6-morfolinopiridin-4-il)-4-metilfenil)-2 (trifluorome-til)isonicotinamida como inibidores raf para o tratamento de câncer |
| CA3146857A1 (en) | 2019-07-11 | 2021-01-14 | Praxis Precision Medicines, Inc. | Formulations of t-type calcium channel modulators and methods of use thereof |
| EP4007585A4 (en) | 2019-08-02 | 2023-11-08 | OneHealthCompany, Inc. | TREATMENT OF CANINE CANCERS |
| RU2749719C1 (ru) * | 2020-10-08 | 2021-06-16 | Нестерук Владимир Викторович | Препарат для лечения анемии, связанной с хроническим заболеванием почек, и способ его получения |
| EP4444299A1 (en) | 2021-12-06 | 2024-10-16 | My Personal Therapeutics Ltd | A combination treatment for cancer |
| WO2024171019A1 (en) * | 2023-02-13 | 2024-08-22 | Alembic Pharmaceuticals Limited | Pharmaceutical composition of trametinib and process of preparation thereof |
| WO2025132408A2 (en) | 2023-12-21 | 2025-06-26 | Synthon B.V. | Solvates of trametinib |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS61205257A (ja) * | 1985-03-08 | 1986-09-11 | Ishihara Sangyo Kaisha Ltd | ベンゾイルウレア系化合物、その製法及びそれを含有する抗ガン剤 |
| US4727077A (en) | 1985-02-20 | 1988-02-23 | Ishihara Sangyo Kaisha Ltd. | Benzoyl urea compounds, process for their production, and antitumorous compositions containing them |
| US5559235A (en) | 1991-10-29 | 1996-09-24 | Glaxo Wellcome Inc. | Water soluble camptothecin derivatives |
| US5342947A (en) | 1992-10-09 | 1994-08-30 | Glaxo Inc. | Preparation of water soluble camptothecin derivatives |
| US5681835A (en) | 1994-04-25 | 1997-10-28 | Glaxo Wellcome Inc. | Non-steroidal ligands for the estrogen receptor |
| US5491237A (en) | 1994-05-03 | 1996-02-13 | Glaxo Wellcome Inc. | Intermediates in pharmaceutical camptothecin preparation |
| GB9716557D0 (en) | 1997-08-06 | 1997-10-08 | Glaxo Group Ltd | Benzylidene-1,3-dihydro-indol-2-one derivatives having anti-cancer activity |
| US6825180B2 (en) | 2001-05-18 | 2004-11-30 | Cell Therapeutics, Inc. | Pyridopyrimidine compounds and their uses |
| MXPA06014478A (es) | 2004-06-11 | 2007-03-21 | Japan Tobacco Inc | Derivados de 5-amino-2, 4, 7-trioxo-3, 4, 7, 8-tetrahidro -2h-pirido[2, 3-d]pirimidina y compuestos relacionados para el tratamiento del cancer. |
| US7378423B2 (en) | 2004-06-11 | 2008-05-27 | Japan Tobacco Inc. | Pyrimidine compound and medical use thereof |
| US8648116B2 (en) * | 2005-07-21 | 2014-02-11 | Ardea Biosciences, Inc. | Derivatives of N-(arylamino) sulfonamides including polymorphs as inhibitors of MEK as well as compositions, methods of use and methods for preparing the same |
| WO2008048469A2 (en) * | 2006-10-13 | 2008-04-24 | Actavis Group Pct Hf | Controlled-release coated dosage forms containing galantamine |
| WO2008060890A2 (en) * | 2006-11-09 | 2008-05-22 | Gilead Colorado, Inc. | Darusentan oral dosage form |
| JO2985B1 (ar) * | 2006-12-20 | 2016-09-05 | Takeda Pharmaceuticals Co | مثبطات كينازmapk/erk |
| UY30892A1 (es) | 2007-02-07 | 2008-09-02 | Smithkline Beckman Corp | Inhibidores de la actividad akt |
| ECSP077628A (es) * | 2007-05-03 | 2008-12-30 | Smithkline Beechman Corp | Nueva composición farmacéutica |
| US20090087489A1 (en) * | 2007-09-25 | 2009-04-02 | Bella Gerber | Imatinib compositions |
| UA103319C2 (en) | 2008-05-06 | 2013-10-10 | Глаксосмитклайн Ллк | Thiazole- and oxazole-benzene sulfonamide compounds |
| JP5719770B2 (ja) * | 2008-07-08 | 2015-05-20 | ベータ・ファーマ・インコーポレイテッドＢｅｔａ Ｐｈａｒｍａ， Ｉｎｃ． | 塩酸イコチニブ、合成物、結晶学的形態、併用薬及びその用途 |
| EA201270453A1 (ru) | 2009-09-23 | 2013-12-30 | ГЛЭКСОСМИТКЛАЙН ЭлЭлСи | Комбинация |
| BR112012006693A2 (pt) | 2009-09-23 | 2015-09-08 | Glaxosmithkline Llc | combinação |
| EA201270475A1 (ru) * | 2009-09-28 | 2012-11-30 | ГЛЭКСОСМИТКЛАЙН ЭлЭлСи | Комбинация |
| SI2488033T1 (sl) | 2009-10-16 | 2019-10-30 | Novartis Ag | Kombinacija, ki vsebuje inhibitor MEK in inhibitor B-RAF |
| KR20120117779A (ko) | 2009-11-17 | 2012-10-24 | 글락소스미스클라인 엘엘씨 | 조합물 |
| EP2608790A4 (en) | 2010-08-26 | 2014-04-02 | Glaxosmithkline Llc | PHARMACEUTICAL COMBINATION OF A VEGFR-INHIBITOR AND A MEK-INHIBITOR FOR THE TREATMENT OF CANCER |
| TWI505828B (zh) | 2010-12-20 | 2015-11-01 | 葛蘭素史克智慧財產（第二）有限公司 | 新穎醫藥組成物 |
| US8977217B1 (en) | 2013-02-20 | 2015-03-10 | Triquint Semiconductor, Inc. | Switching device with negative bias circuit |
| CZ2015278A3 (cs) | 2015-04-24 | 2016-11-02 | Zentiva, K.S. | Krystalické formy trametinibu |
-
2011
- 2011-12-16 TW TW100146692A patent/TWI505828B/zh active
- 2011-12-18 JO JOP/2011/0385A patent/JO3594B1/ar active
- 2011-12-19 AR ARP110104773A patent/AR084102A1/es not_active Application Discontinuation
- 2011-12-19 UY UY0001033818A patent/UY33818A/es active IP Right Grant
- 2011-12-20 PL PL22209107.6T patent/PL4159205T3/pl unknown
- 2011-12-20 EP EP22209107.6A patent/EP4159205B1/en active Active
- 2011-12-20 LT LTEP22209104.3T patent/LT4159204T/lt unknown
- 2011-12-20 MY MYPI2013701038A patent/MY170501A/en unknown
- 2011-12-20 MX MX2013007073A patent/MX2013007073A/es active IP Right Grant
- 2011-12-20 FI FIEP22209104.3T patent/FI4159204T3/fi active
- 2011-12-20 RS RS20240518A patent/RS65496B1/sr unknown
- 2011-12-20 DK DK11849974.8T patent/DK2654736T3/da active
- 2011-12-20 PL PL22209104.3T patent/PL4159204T3/pl unknown
- 2011-12-20 ES ES22209107T patent/ES2985024T3/es active Active
- 2011-12-20 SG SG2013044037A patent/SG191054A1/en unknown
- 2011-12-20 EA EA201390913A patent/EA025198B1/ru not_active IP Right Cessation
- 2011-12-20 MA MA36106A patent/MA34883B1/fr unknown
- 2011-12-20 ES ES11849974T patent/ES2820536T3/es active Active
- 2011-12-20 JP JP2013546310A patent/JP6126014B2/ja active Active
- 2011-12-20 RS RS20240519A patent/RS65497B1/sr unknown
- 2011-12-20 CA CA2822701A patent/CA2822701C/en active Active
- 2011-12-20 FI FIEP22209107.6T patent/FI4159205T3/fi active
- 2011-12-20 PT PT118499748T patent/PT2654736T/pt unknown
- 2011-12-20 PT PT222091076T patent/PT4159205T/pt unknown
- 2011-12-20 DK DK22209107.6T patent/DK4159205T3/da active
- 2011-12-20 PL PL11849974T patent/PL2654736T3/pl unknown
- 2011-12-20 PE PE2013001442A patent/PE20140040A1/es active IP Right Grant
- 2011-12-20 UA UAA201309128A patent/UA113158C2/uk unknown
- 2011-12-20 HR HRP20201409TT patent/HRP20201409T1/hr unknown
- 2011-12-20 HR HRP20240564TT patent/HRP20240564T1/hr unknown
- 2011-12-20 US US13/330,949 patent/US8580304B2/en active Active
- 2011-12-20 WO PCT/US2011/066021 patent/WO2012088033A2/en not_active Ceased
- 2011-12-20 KR KR1020137019029A patent/KR101911109B1/ko active Active
- 2011-12-20 US US13/991,705 patent/US20130266649A1/en not_active Abandoned
- 2011-12-20 HU HUE22209107A patent/HUE066526T2/hu unknown
- 2011-12-20 PT PT222091043T patent/PT4159204T/pt unknown
- 2011-12-20 AU AU2011349422A patent/AU2011349422B2/en active Active
- 2011-12-20 ES ES22209104T patent/ES2982775T3/es active Active
- 2011-12-20 LT LTEP22209107.6T patent/LT4159205T/lt unknown
- 2011-12-20 EP EP20179788.3A patent/EP3808343A1/en active Pending
- 2011-12-20 SI SI201132109T patent/SI4159204T1/sl unknown
- 2011-12-20 HU HUE11849974A patent/HUE050788T2/hu unknown
- 2011-12-20 LT LTEP11849974.8T patent/LT2654736T/lt unknown
- 2011-12-20 HU HUE22209104A patent/HUE066525T2/hu unknown
- 2011-12-20 DK DK22209104.3T patent/DK4159204T3/da active
- 2011-12-20 BR BR112013015602-3A patent/BR112013015602B1/pt active IP Right Grant
- 2011-12-20 EP EP22209104.3A patent/EP4159204B1/en active Active
- 2011-12-20 NZ NZ612157A patent/NZ612157A/en unknown
- 2011-12-20 SI SI201131918T patent/SI2654736T1/sl unknown
- 2011-12-20 EP EP11849974.8A patent/EP2654736B1/en not_active Revoked
- 2011-12-20 SI SI201132108T patent/SI4159205T1/sl unknown
- 2011-12-20 HR HRP20240563TT patent/HRP20240563T1/hr unknown
- 2011-12-20 PH PH1/2013/501209A patent/PH12013501209A1/en unknown
- 2011-12-20 CN CN201180066851.0A patent/CN103998041B/zh active Active
-
2013
- 2013-06-07 ZA ZA2013/04189A patent/ZA201304189B/en unknown
- 2013-06-10 IL IL226855A patent/IL226855A/en active IP Right Grant
- 2013-06-18 DO DO2013000138A patent/DOP2013000138A/es unknown
- 2013-06-18 CL CL2013001779A patent/CL2013001779A1/es unknown
- 2013-07-19 CR CR20130352A patent/CR20130352A/es unknown
- 2013-10-02 US US14/044,139 patent/US9271941B2/en active Active
- 2013-12-11 US US14/103,092 patent/US9399021B2/en active Active
- 2013-12-11 US US14/103,193 patent/US9155706B2/en active Active
-
2017
- 2017-01-19 JP JP2017007796A patent/JP2017137299A/ja not_active Withdrawn
-
2020
- 2020-09-24 CY CY20201100905T patent/CY1123376T1/el unknown
-
2021
- 2021-05-27 AR ARP210101433A patent/AR122185A2/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2013001779A1 (es) | Comprimido farmaceutico que comprende el solvato de dimetilsulfoxido de n-{3-[3-ciclopropil-5-(2-fluoro-4-yodo-fenilamino)-6,8-dimetil-2,4,7-trioxo-3,4,6,7-tetrahidro-2h-pirido[4,3-d]pirimidin-1-il]fenil}acetamida; procedimiento de preparacion; y su uso para tratar el cancer. | |
| AR094842A1 (es) | Formas sólidas de un inhibidor cdk4/6 selectivo | |
| CL2013001497A1 (es) | Metodo para producir un preparado farmaceutico que contiene un inhibidor de la bomba de protones y un aine en forma de granulos esfericos; preparado farmaceutico; y su uso para el tratamiento del dolor e inflamacion en reumatismo, contusiones, esguinces y artrosis. | |
| CR20150232A (es) | Imidazo [1,2-a] piridincarboxamidas aminosustituidas y su uso | |
| ZA201204871B (en) | Thiazolo[5,4-d]pyrimidines and their use as agrochemicals | |
| ZA201300002B (en) | Novel processes for the preparation of phenylcyclopropylamine derivatives and use thereof for preparing ticagrelor | |
| ZA201300100B (en) | Indolizine derivatives,process for the preparation thereof and therapeutic use thereof | |
| CL2014003232A1 (es) | Formulaciones y métodos para la administración vaginal de antiprogestinas. | |
| IL236170A0 (en) | 2,3-dihydro-h1-imidazo[a-1,2]pyrimidin-5-one and 1,2,3,4-tetrahydropyrimido[a-1,2]pyrimidin-6-one derivatives containing modified morpholine, their preparation and pharmaceutical use their | |
| BR112013007022A2 (pt) | uso de estearato de magnésio, formulação farmacêutica e inalador de pó seco | |
| PT2448940E (pt) | Derivados de 6,7,8,9-tetra-hidro-pirimido{1,2-α} pirimidin- 4-ona, sua preparação e sua utilização farmacêutica | |
| UY35157A (es) | Nueva composición farmacéutica conteniendo dimetilsulfóxido | |
| NI201200157A (es) | Composiciones farmacéuticas que comprenden hidromorfona y naloxona | |
| CL2015001085A1 (es) | Formulacion de liberación prolongada que comprende oprozomib y ademas uno o mas polimeros farmaceuticamente aceptables; metodo de preparacion de la formulacion; metodo para tratar cancer. | |
| PT2448939T (pt) | Derivados de 2,3-dihidro-1h-imidazo{1,2-a}pirimidin-5-ona, sua preparação e sua utilização farmacêutica | |
| SI2588480T1 (sl) | Derivati 3,4-dihidropirolo(1,2-a)pirazina-2,8(1H)-dikarboksamida, njihova priprava in terapevtska uporaba | |
| CO6801756A2 (es) | Derivas de tieno [2,3-d] pirimidina y su uso para el tratamiento de la arritimia | |
| SG11201508653QA (en) | PYRAZINO[1,2-a]INDOLE COMPOUNDS, THEIR PREPARATION AND USE IN MEDICAMENTS | |
| CL2014003028A1 (es) | Formulacion parenteral de clorhidrato de esmolol; metodo de produccion; kit farmaceutico; uso para tratar descompensacion cardiaca y/o renal y/o hipernatremia y/o acidosis hipercloramica. | |
| FR2969612B1 (fr) | Nouveaux derives de 2,3-dihydro-1h-imidazo{1,2-a}pyrimidin-5-one, leur preparation et leur utilisation pharmaceutique | |
| CO6781490A2 (es) | Nueva composición farmacéutica | |
| GB201115338D0 (en) | Dual purpose leg & table support for tablet or net-book computer, E-reader or hand-held game console |